Skip to content
Opening soonHORIZON-HLTH-2027-03-TOOL-02HaDEAOne-off

Advancing bio-printing of living cells for regenerative medicine

Advancing 3D bioprinting of living cells for regenerative medicine.

Horizon Europe research action (RIA) bringing tissue-specific 3D bioprinting of living cells for tissue repair and transplantation in regenerative medicine closer to clinical application.

Opening soon
197
days until opening
Opens on 3 June 2027
HORIZON-HLTH-2027-03-TOOL-02
View all deadlines
Beta

This grant database is in beta

Until the official launch on 1 January 2027 we are making the final improvements. Our editors check every scheme, but details may still be incomplete or out of date. Check the official publication before you apply.

In brief

What is Advancing bio-printing of living cells for regenerative medicine?

Who
A consortium of at least three independent organisations from three different countries, of which at least one from an EU Member State and the others from Member States or Associated Countries; companies of any size, research organisations, public authorities, foundations and associations can take part, and organisations from the United States can also receive funding. Organisations established in China are excluded; the Joint Research Centre may join after selection without funding or as an associated partner.
General Annex B (Entities eligible to participate; Entities eligible for funding; Consortium composition); Destination; Specific conditions, Eligibility conditions
What for
A research and innovation action that further develops tissue-specific 3D bioprinting of living cells for regenerative medicine towards clinical application. The aim is to bring regenerative treatments with bioprinted tissues closer to the patient.
Expected Outcome; Scope
What you get
A grant covering 100% of eligible costs; the Commission considers an EU contribution of €7 to 10 million per project appropriate. The indicative budget for the topic is €39.3 million, expected to fund 4 projects.
Specific conditions (Expected EU contribution per project, Indicative budget); General Annex G, Funding rates
What you need to do
Submit a proposal in a single stage via the Funding & Tenders Portal from 3 June 2027 until 16 September 2027 at the latest (17:00 Brussels time), with application form Part A, Part B and, where applicable, an annex on clinical studies. Independent experts evaluate and rank the proposals; the results follow around 5 months after the deadline.
Budget overview; Application and evaluation forms; General Annex F

Built from the details on this page, with nothing added by us.

Purpose & impact

Why does this scheme exist?

Bringing regenerative treatments with bioprinted tissues closer to the patient.

01
Access to bioprinting units
Biomedical researchers from academia and industry gain access to complete bioprinting units for regenerating human tissue.
02
Safe use by healthcare professionals
Healthcare professionals receive information on the safe and effective use of equipment for advanced therapies with bioprinted human tissue.
03
Treating unmet medical needs
Healthcare providers have the means to treat conditions with an unmet medical need.
04
Personalised treatment
Patients benefit from a personalised approach to their condition thanks to bioprinted solutions for regenerative medicine.
Description

About the scheme

Compiled from passages of the scheme's official publication, with nothing added by us.

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to most of the following expected outcomes: - Biomedical scientists from academia and industry will gain access to entire bio-printing units designed to regenerate human tissue. - Healthcare professionals acquire information on the safe and effective use of equipment enabling advanced therapies with bio-printed human tissue. - Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need. - Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.

Am I eligible?

Conditions

Quoted verbatim from the scheme, with the article that sets each condition.

01
To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions … – the Overseas Countries and Territories (OCTs) linked to the Member States … – countries associated to Horizon Europe … – the following low- and middle-income countries
02
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.
03
Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.
04
Legal entities established in China are not eligible to participate in both Research and Innovation Actions (RIAs) and Innovation Actions (IAs) falling under this destination.
05
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
06
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
07
The Joint Research Centre (JRC) may participate as member of the consortium selected for funding as a beneficiary with zero funding, or as an associated partner.
All sizes
Micro< 10 FTE
Small< 50 FTE
Medium< 250 FTE
Large≥ 250 FTE
Themes
Onderzoek, ontwikkeling en innovatieZiekenhuiszorg en medische zorgGezondheid, zorg en welzijn
Project phase
ResearchDevelopment
Funding

What do you get?

100% of your eligible project costs.

Note on the maximum
No binding maximum; the Commission considers an EU contribution of €7 million to €10 million per project appropriate.
€39.3m · Indicative topic budget, expected to fund 4 projects.
Budget status
Not published by the source
The sources do not say how much budget is left (checked 18 November 2026).
No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants), and the same costs may never be declared under two different EU actions (General Annex G).
Type
Direct grant (non-repayable)
Calendar

Deadlines & cycles

3
JUN
HORIZON-HLTH-2027-03-TOOL-02 opens 3 June 2027
Budget overview
Cycle: Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F). General Annex F, Indicative timetable for evaluation and for signature of the grant agreement
Application

How do you apply?

Pre-registration
Required, before the full application
Required attachments
  • Application form Part A: administrative details of the participants and summarised budget (to be completed online)
  • Application form Part B: technical description of the project (PDF, maximum 40 pages)
  • Clinical studies annex (template in the submission system) for the clinical studies included in the proposal
Procedure
Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).
Eligible costs

What can the money be spent on?

Personnel costs
Materials
Subcontracting
Equipment
Land
Not eligible
Buildings
Not eligible
Overheads
Travel costs
Other costs
Actual costs in accordance with the Horizon Europe Model Grant Agreement (personnel, subcontracting, travel, equipment and other goods and services costs) plus 25% flat-rate indirect costs. Funding rate 100% (General Annex G).
Downloads

Files & forms

Changes

What has changed?

10 November 2026scheme · version 5

Subtitle
Subtitle: ChangedShow
Before

3D-bioprinting van levende cellen verder brengen voor regeneratieve geneeskunde.

Now

Advancing 3D bioprinting of living cells for regenerative medicine.

Description
Description: ChangedShow
Before

Projecten ontwikkelen weefselspecifieke, functionele 3D-bioprinting van levende cellen voor regeneratieve geneeskunde verder en pakken de knelpunten richting klinische toepassing aan, zoals kwaliteit, veiligheid en opschaalbaarheid van gebioprinte celconstructen. In de VS gevestigde entiteiten kunnen EU-financiering ontvangen.

Now

Projects further develop tissue-specific, functional 3D bioprinting of living cells for regenerative medicine and address the bottlenecks towards clinical application, such as quality, safety and scalability of bioprinted cell constructs. Entities established in the US can receive EU funding.

Short description
Short description: ChangedShow
Before

Horizon Europe-onderzoeksactie (RIA) die weefselspecifieke 3D-bioprinting van levende cellen voor weefselherstel en transplantatie in de regeneratieve geneeskunde dichter bij klinische toepassing brengt.

Now

Horizon Europe research action (RIA) bringing tissue-specific 3D bioprinting of living cells for tissue repair and transplantation in regenerative medicine closer to clinical application.

Cycle
Cycle: ChangedShow
Before

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Now

Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F).

Note on the total budget
Note on the total budget: ChangedShow
Before

Indicatief topicbudget, naar verwachting 4 projecten.

Now

Indicative topic budget, expected to fund 4 projects.

Note on the maximum
Note on the maximum: ChangedShow
Before

Geen bindend maximum; de Commissie acht € 7 mln tot € 10 mln EU-bijdrage per project passend.

Now

No binding maximum; the Commission considers an EU contribution of €7 million to €10 million per project appropriate.

Cumulation
Cumulation: ChangedShow
Before

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Now

No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants), and the same costs may never be declared under two different EU actions (General Annex G).

Search engine title
Bioprinting voor regeneratieve geneeskunde (Horizon) becomes Bioprinting for regenerative medicine (Horizon)
Search engine description
Search engine description: ChangedShow
Before

Horizon Europe-onderzoeksactie naar 3D-bioprinting van levende cellen voor regeneratieve geneeskunde; € 7-10 mln EU-bijdrage per project.

Now

Horizon Europe research action on 3D bioprinting of living cells for regenerative medicine; €7-10 million EU contribution per project.

Keywords
bioprinten, Cluster 1 Health, geavanceerde therapieën, Horizon Europe, HORIZON-HLTH-2027-03-TOOL-02, regeneratieve geneeskunde, weefselherstel becomes advanced therapies, bioprinting, Cluster 1 Health, Horizon Europe, HORIZON-HLTH-2027-03-TOOL-02, regenerative medicine, tissue repair
Language
Dutch (Netherlands) becomes British English
Required attachments
Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage klinische studies (template in het indieningssysteem) voor de klinische studies die het voorstel omvat becomes Application form Part A: administrative details of the participants and summarised budget (to be completed online); Application form Part B: technical description of the project (PDF, maximum 40 pages); Clinical studies annex (template in the submission system) for the clinical studies included in the proposal
Procedure
Procedure: ChangedShow
Before

Aanvragen via het Funding & Tenders Portal met een EU Login en een PIC-nummer; single-stage; deadline 17:00 uur Brusselse tijd; beheerd door European Health and Digital Executive Agency (HaDEA).

Now

Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).

Notes per cost type
Notes per cost type: ChangedShow
Before

Other costs: Werkelijke kosten volgens de Horizon Europe-modelsubsidieovereenkomst (personeel, onderaanneming, reis-, apparatuur- en overige goederen- en dienstenkosten) plus 25% forfaitaire indirecte kosten. Financieringspercentage 100% (General Annex G).

Now

Other costs: Actual costs in accordance with the Horizon Europe Model Grant Agreement (personnel, subcontracting, travel, equipment and other goods and services costs) plus 25% flat-rate indirect costs. Funding rate 100% (General Annex G).

Why this scheme
Why this scheme: ChangedShow
Before

Regeneratieve behandelingen met gebioprinte weefsels dichter bij de patiënt brengen.

Now

Bringing regenerative treatments with bioprinted tissues closer to the patient.

In brief
In brief: ChangedShow
Before

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen, en ook organisaties uit de Verenigde Staten kunnen financiering krijgen. In China gevestigde organisaties zijn uitgesloten; het Joint Research Centre kan na selectie zonder financiering of als geassocieerde partner aansluiten.

What for: Een onderzoeks- en innovatieactie die weefselspecifieke 3D-bioprinting van levende cellen voor regeneratieve geneeskunde verder ontwikkelt richting klinische toepassing. Het doel is regeneratieve behandelingen met gebioprinte weefsels dichter bij de patiënt te brengen.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot 10 miljoen per project passend. Het indicatieve budget voor het topic is € 39,3 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien vanaf 3 juni 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A, deel B en zo nodig een bijlage over klinische studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt rond 5 maanden na de deadline.

Now

Who: A consortium of at least three independent organisations from three different countries, of which at least one from an EU Member State and the others from Member States or Associated Countries; companies of any size, research organisations, public authorities, foundations and associations can take part, and organisations from the United States can also receive funding. Organisations established in China are excluded; the Joint Research Centre may join after selection without funding or as an associated partner.

What for: A research and innovation action that further develops tissue-specific 3D bioprinting of living cells for regenerative medicine towards clinical application. The aim is to bring regenerative treatments with bioprinted tissues closer to the patient.

What you get: A grant covering 100% of eligible costs; the Commission considers an EU contribution of €7 to 10 million per project appropriate. The indicative budget for the topic is €39.3 million, expected to fund 4 projects.

What you need to do: Submit a proposal in a single stage via the Funding & Tenders Portal from 3 June 2027 until 16 September 2027 at the latest (17:00 Brussels time), with application form Part A, Part B and, where applicable, an annex on clinical studies. Independent experts evaluate and rank the proposals; the results follow around 5 months after the deadline.

Goals
Goals: 4 removed, 4 newShow
Removed

Toegang tot bioprintunits Biomedische onderzoekers uit academie en industrie krijgen toegang tot complete bioprintunits voor het regenereren van menselijk weefsel.

Veilig gebruik door zorgprofessionals Zorgprofessionals krijgen informatie over veilig en effectief gebruik van apparatuur voor geavanceerde therapieën met gebioprint menselijk weefsel.

Behandeling van onvervulde medische behoeften Zorgaanbieders beschikken over middelen om aandoeningen met een onvervulde medische behoefte te behandelen.

Gepersonaliseerde behandeling Patiënten profiteren van een gepersonaliseerde aanpak van hun aandoening dankzij gebioprinte oplossingen voor regeneratieve geneeskunde.

New

Access to bioprinting units Biomedical researchers from academia and industry gain access to complete bioprinting units for regenerating human tissue.

Safe use by healthcare professionals Healthcare professionals receive information on the safe and effective use of equipment for advanced therapies with bioprinted human tissue.

Treating unmet medical needs Healthcare providers have the means to treat conditions with an unmet medical need.

Personalised treatment Patients benefit from a personalised approach to their condition thanks to bioprinted solutions for regenerative medicine.

Show 4 earlier versions

19 October 2026scheme · version 4

Conditions
Conditions: 2 removed, 7 newShow
Removed

Consortium van minimaal 3 partijen Drie onafhankelijke juridische entiteiten uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minimaal één uit een lidstaat (General Annex B).

Entiteiten uit de Verenigde Staten komen in aanmerking In de VS gevestigde juridische entiteiten kunnen EU-financiering ontvangen, als erkenning van de openstelling van NIH-programma's voor Europese onderzoekers.

New

To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions … – the Overseas Countries and Territories (OCTs) linked to the Member States … – countries associated to Horizon Europe … – the following low- and middle-income countries

Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.

Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.

Legal entities established in China are not eligible to participate in both Research and Innovation Actions (RIAs) and Innovation Actions (IAs) falling under this destination.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).

The Joint Research Centre (JRC) may participate as member of the consortium selected for funding as a beneficiary with zero funding, or as an associated partner.

In brief
In brief: AddedShow
Now

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen, en ook organisaties uit de Verenigde Staten kunnen financiering krijgen. In China gevestigde organisaties zijn uitgesloten; het Joint Research Centre kan na selectie zonder financiering of als geassocieerde partner aansluiten.

What for: Een onderzoeks- en innovatieactie die weefselspecifieke 3D-bioprinting van levende cellen voor regeneratieve geneeskunde verder ontwikkelt richting klinische toepassing. Het doel is regeneratieve behandelingen met gebioprinte weefsels dichter bij de patiënt te brengen.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot 10 miljoen per project passend. Het indicatieve budget voor het topic is € 39,3 miljoen, naar verwachting voor 4 projecten.

What you need to do: Dien vanaf 3 juni 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A, deel B en zo nodig een bijlage over klinische studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt rond 5 maanden na de deadline.

18 October 2026scheme · version 3

About the scheme
About the scheme: AddedShow
Now

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to most of the following expected outcomes: - Biomedical scientists from academia and industry will gain access to entire bio-printing units designed to regenerate human tissue. - Healthcare professionals acquire information on the safe and effective use of equipment enabling advanced therapies with bio-printed human tissue. - Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need. - Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution.

16 October 2026scheme · version 2

Cycle
Cycle: AddedShow
Now

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Cumulation
Cumulation: AddedShow
Now

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Keywords
Added: bioprinten, Cluster 1 Health, geavanceerde therapieën, Horizon Europe, HORIZON-HLTH-2027-03-TOOL-02, regeneratieve geneeskunde, weefselherstel
Required attachments
Added: Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 40 pagina's); Bijlage klinische studies (template in het indieningssysteem) voor de klinische studies die het voorstel omvat
Goals
Goals: 4 newShow
New

Toegang tot bioprintunits Biomedische onderzoekers uit academie en industrie krijgen toegang tot complete bioprintunits voor het regenereren van menselijk weefsel.

Veilig gebruik door zorgprofessionals Zorgprofessionals krijgen informatie over veilig en effectief gebruik van apparatuur voor geavanceerde therapieën met gebioprint menselijk weefsel.

Behandeling van onvervulde medische behoeften Zorgaanbieders beschikken over middelen om aandoeningen met een onvervulde medische behoefte te behandelen.

Gepersonaliseerde behandeling Patiënten profiteren van een gepersonaliseerde aanpak van hun aandoening dankzij gebioprinte oplossingen voor regeneratieve geneeskunde.

8 October 2026scheme · version 1 · first publication

Source

Contact & source

Funding body
European Health and Digital Executive Agency
Last verified
11 November 2026 by the Twin editors
Start your application

Start your HORIZON-HLTH-2027-03-TOOL-02 application
in Twin.

Twin helps you write your application, based on the scheme and your own project documents. You stay in control of every text.